Current immunotherapy agents used in NSCLC inhibit the checkpoint proteins that down-regulate T cells, including programmed death-1 (PD-1)/PD-L1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (7). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.